Circio (CRNA) Biologics World Nordics 2025 Presentation summary

circRNA technology overview

• Circular RNA (circRNA) offers 70x longer half-life and 15x higher protein expression than mRNA, enhancing potency and safety of nucleic acid medicines.

• circRNA's modularity enables new mechanisms of action, including 'remove & replace' gene therapy concepts.

• Circio scientists were among the first to describe human circRNA and its therapeutic potential.

• The field is experiencing high deal activity, with major investments and partnerships in circRNA technologies.

circVec platform features and differentiation

• circVec turns patient cells into circRNA factories, enabling potent and durable protein expression.

• Platform offers months-to-years expression durability, outperforming synthetic mRNA and circRNA approaches.

• Technological differentiation includes suitability for gene therapy, vaccines, and compatibility with existing manufacturing systems.

• Circio is recognized as a leader in circRNA, with international attention and unique technology.

circVec platform development and performance

• circVec design is inspired by natural circRNA biogenesis, optimized through multiple generations for maximal expression.

• circVec 3.0 achieves a 27x increase in protein expression over earlier versions.

• In vitro, circVec 2.1 delivers ~10x higher expression than mRNA vectors and maintains expression for over 6 months in vivo after a single injection.

• At low doses, circVec 2.1 shows up to 15x higher expression than mRNA at 170 days post-injection.

• Bioinformatic analysis confirms >70x longer in vivo half-life for circRNA compared to mRNA.